Currently out of the existing stock ratings of Terence Flynn, 159 are a HOLD (42.18%), 37 are a SELL (9.81%), 181 are a BUY (48.01%).

Terence Flynn

Work Performance Price Targets & Ratings Chart

Analyst Terence Flynn, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 68.45% that have a potential upside of 24.57% achieved within 221 days. Previously, Terence Flynn worked at GOLDMAN SACHS.

Terence Flynn’s has documented 784 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PFE, Pfizer at 17-Dec-2025.

Wall Street Analyst Terence Flynn

Analyst best performing recommendations are on TBIO (TELESIS BIO).
The best stock recommendation documented was for ARVN (ARVINAS) at 11/13/2023. The price target of $20 was fulfilled within 2 days with a profit of $3.41 (20.55%) receiving and performance score of 102.77.

Average potential price target upside

of $125.84 (27.22%) on REGN (REGENERON PHARMACEUTICALS).
of $79.75 (11.07%) on FGEN (FIBROGEN).
of $96.85 (25.41%) on LLY (ELI LILLY AND COMPANY).

ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals AMGN Amgen ARVN Arvinas BIIB Biogen BPMC Blueprint Medicines Corp CELG Celgene FGEN FibroGen GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany OGN Organon PFE Pfizer REGN Regeneron Pharmaceuticals RVNC Revance The TBIO Telesis Bio AGIO Agios Pharm VRTX Vertex Pharmaceuticals ABBV AbbVie BMY Bristol-Myers Squibb Company CLVS Clovis Oncology JNJ Johnson & Johnson RPRX Royalty Pharma Plc UTHR United Therapeutics XLRN Acceleron Pharma NTLA Intellia Therapeutics AGN Allergan plc CCCC C4 Therapeutics CRSP Crispr Therapeutics AG CTMX CytomX Therapeutics ITMN InterMune MGTA Magenta Therapeutics RCUS Arcus Biosciences NRIX Nurix Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd BNTX BioNTech SE ALMS Alumis Common Stock PRME Prime Medicine, Common Stock ISEE IVERIC bio

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score